Drug
Lotiglipron clinical trials
Also written PF-07081532.
- studies test it
- 9
- open now
- 0
- in phase 3
- 0
- first study started
- 2019
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2022 (3)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 0
Often tested with
Tested in the same studies.
Itraconazole (1) · Clopidogrel (1) · Semaglutide (1) · Rosuvastatin (1)
Studies
Open first, then newest update. How each study uses lotiglipron is read from its arms, and is right about nine times in ten.
Testing it · 9
- A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity RangeTerminatedPhase 1PfizerNCT05671653Written as PF-07081532
- A Drug-Drug Interaction Study to Estimate the Effect of PF-07081532 on the Pharmacokinetics of Dabigatran and Rosuvastatin in Overweight or Obese Adult ParticipantsTerminatedPhase 1PfizerNCT05788328Written as PF-07081532
- A Clinical Trial of the Study Medicine (PF-07081532) in People With Diabetes and Kidney DysfunctionTerminatedPhase 1PfizerNCT05510245Written as PF-07081532
- A Drug-Drug Interaction Study to Examine the Impact of Itraconazole and Cyclosporine on PF-07081532 Pharmacokinetics in Overweight or Obese AdultsCompletedPhase 1PfizerNCT05745701Written as PF-07081532
- A Study to Understand How the Study Medicine (PF-07081532) is Processed in People With Liver DysfunctionCompletedPhase 1PfizerNCT05478603Written as PF-07081532
- Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes MellitusCompletedPhase 1PfizerNCT05158244Written as PF-07081532
- Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With ObesityTerminatedPhase 2PfizerNCT05579977Written as PF-07081532
- Multiple Escalating Oral Doses Study of PF-07081532 in Adult Participants With Type 2 Diabetes MellitusCompletedPhase 1PfizerNCT04305587Written as PF-07081532
- Study of Single Ascending Doses of PF-07081532 in Healthy Adult ParticipantsCompletedPhase 1PfizerNCT04148209Written as PF-07081532
Codes
What other systems call lotiglipron · ClinicalTrials.gg INT018599
- UNII (FDA) YI10W1K93ALOTIGLIPRONConfirmed FDA, Wikidata
- Wikidata Q120491736lotiglipronConfirmed FDA, Wikidata
- NCI Thesaurus C199066LotiglipronOne source FDA
- DrugBank DB21631One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | YI10W1K93A | LOTIGLIPRON | Confirmed FDA, Wikidata |
| Wikidata | Q120491736 | lotiglipron | Confirmed FDA, Wikidata |
| NCI Thesaurus | C199066 | Lotiglipron | One source FDA |
| DrugBank | DB21631 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.